What is Cradle Genomics?
Headquartered in San Diego, California, Cradle Genomics is at the forefront of innovation in prenatal diagnostics. The company is dedicated to developing advanced solutions for genetic analysis and monitoring pregnancy health from the earliest stages. Their work aims to provide critical insights and improve outcomes for expectant parents and healthcare providers.
How much funding has Cradle Genomics raised?
Cradle Genomics has raised a total of $23.1M across 2 funding rounds:
Series A
$17.1M
Debt
$6M
Series A (2019): $17.1M with participation from Sea Lane Ventures, Alexandria Real Estate Equities, Axon Ventures, Section 32, Listwin Ventures, and Illumina Ventures
Debt (2020): $6M led by Pacific West Bank
Key Investors in Cradle Genomics
Sea Lane Ventures
Sea Lane Ventures is an investment firm that likely focuses on strategic capital allocation, supporting companies with significant growth potential.
Alexandria Real Estate Equities
Alexandria Real Estate Equities is a real estate investment trust specializing in properties for the life sciences industry, indicating a focus on infrastructure and ecosystem support for biotech and health tech companies.
Section 32
Section 32 is a venture capital firm known for investing in cutting-edge technology, particularly within the healthcare and life sciences sectors, suggesting a strategic interest in disruptive innovation.
What's next for Cradle Genomics?
With a substantial enterprise-level funding context, Cradle Genomics is positioned for significant scaling and further research and development. The recent strategic investment, likely aimed at accelerating product commercialization and expanding market reach, suggests a pivotal phase for the company. Future endeavors will likely focus on clinical validation, regulatory approvals, and broader adoption of their pioneering technologies in the maternal-fetal medicine sector.
See full Cradle Genomics company page
